

**15 -ാം കേരള നിയമസഭ**

**12 -ാം സമ്മേളനം**

**നക്ഷത്ര ചിഹ്നം ഇല്ലാത്ത ചോദ്യം നം. 2140**

**14-10-2024 - ൽ മറുപടിയ്ക്ക്**

**അമീബിക് മസ്തിഷ്ക ജ്വരം**

ചോദ്യം		ഉത്തരം	
<b>ശ്രീ പി. അബൂൽ ഹമീദ്</b>		<b>ശ്രീമതി വീണാ ജോർജ്ജ്</b> <b>(ആരോഗ്യ- വനിത-ശിശുവികസന വകുപ്പ് മന്ത്രി)</b>	
(എ)	സംസ്ഥാനത്ത് അമീബിക് മസ്തിഷ്ക ജ്വരം കാരണം ചികിത്സ തേടിയവരുടെയും, മരണപ്പെട്ടവരുടെയും വിവരങ്ങൾ ജില്ലാടിസ്ഥാനത്തിൽ ലഭ്യമാക്കാമോ;	(എ)	സംസ്ഥാനത്ത് 2024 ജനുവരി മുതൽ 8/10/2024 വരെ അമീബിക് മസ്തിഷ്കജ്വരം കാരണം ചികിത്സ തേടിയവരുടെയും, മരണപ്പെട്ടവരുടെയും വിവരങ്ങൾ <b>അനുബന്ധം 1</b> ആയി ചേർക്കുന്നു.
(ബി)	അമീബിക് മസ്തിഷ്ക ജ്വരത്തിന് നിലവിലുള്ള ചികിത്സാ രീതി സംബന്ധിച്ച വിശദാംശങ്ങൾ ലഭ്യമാക്കാമോ;	(ബി)	അമീബിക് മസ്തിഷ്കജ്വരത്തിന്റെ തടയൽ, രോഗ നിർണ്ണയം, ചികിത്സ എന്നിവ സംബന്ധിച്ച സാങ്കേതിക മാർഗ്ഗനിർദ്ദേശങ്ങൾ സ.ഉ.(സാധാ)നം. 1760/2024/ആ.ക.വ തീയതി 20/07/2024 പ്രകാരം പുറപ്പെടുവിച്ചിട്ടുണ്ട്. ആയതിന്റെ പകർപ്പ് <b>അനുബന്ധം 2</b> ആയി ചേർക്കുന്നു.  സെറിബ്രോ സ്പൈനൽ ഫ്ലൂയിഡ് പരിശോധനയിലൂടെ അമീബിക് മസ്തിഷ്കജ്വരം സ്ഥിരീകരിച്ചതിനുശേഷം മാർഗ്ഗനിർദ്ദേശങ്ങൾ പ്രകാരമുള്ള മരുന്നുകൾ വിദഗ്ദ്ധ ഡോക്ടർമാരുടെ മേൽനോട്ടത്തിൽ നൽകുകയാണ് നിലവിലെ ചികിത്സാരീതി.
(സി)	അമീബിക് മസ്തിഷ്ക ജ്വരം തടയുന്നതിന് സ്വീകരിച്ചു വരുന്ന നടപടികൾ എന്തെല്ലാമാണെന്നും, ചികിത്സയ്ക്കായി സൗകര്യം ഒരുക്കിയിട്ടുള്ള ആരോഗ്യ സ്ഥാപനങ്ങൾ എവിടെയൊക്കെയാണെന്നും അറിയിക്കാമോ; വിശദാംശങ്ങൾ ലഭ്യമാക്കാമോ?	(സി)	അമീബിക് മസ്തിഷ്ക ജ്വരം റിപ്പോർട്ട് ചെയ്യപ്പെട്ട സാഹചര്യത്തിൽ തന്നെ വിദഗ്ദ്ധരുമായി ചേർന്നു ഉന്നതതല അവലോകന യോഗം ചേരുകയും മനുഷ്യരിൽ നിന്ന് മനുഷ്യരിലേക്ക് പകരില്ല എന്നും പരിഭ്രാന്തരാകരുതെന്നും അറിയിച്ചു. കൂടാതെ പനി, ഛർദ്ദി, തലവേദന, ജെന്നി, സ്വബോധം നഷ്ടപ്പെടുന്ന അവസ്ഥ എന്നീ ലക്ഷണങ്ങളുമായി ചികിത്സ തേടുന്ന, കുളങ്ങളിലും നദികളിലും ഉള്ള വെള്ളവുമായി സമ്പർക്കമുള്ളവർക്കു amoebic meningo encephalitisനുള്ള ടെസ്റ്റിംഗ് നടത്തുന്നതിനും ചികിത്സ ലഭ്യമാക്കുന്നതിനുമുള്ള നടപടികൾ സ്വീകരിച്ചിട്ടുണ്ട്. കൂടാതെ രോഗ ലക്ഷണങ്ങൾ കണ്ടാൽ ഉടൻ തന്നെ വൈദ്യസഹായം തേടണമെന്നും കെട്ടിക്കിടക്കുന്ന വെള്ളത്തിൽ നീന്തുന്നത് പരമാവധി ഒഴിവാക്കുന്നതിനും പൊതുജനങ്ങളോട് നിർദ്ദേശിച്ചിട്ടുണ്ട്.

നീന്തൽക്കുളങ്ങളിലെയും വാട്ടർ തീം പാർക്കുകളിലെയും വെള്ളം ശരിയായ അണുവിമുക്തമാക്കൽ ഉറപ്പാക്കാൻ നിർദ്ദേശിച്ചിട്ടുണ്ട്. ഗുരുതരമായ അവസ്ഥയെ ചികിത്സിക്കാൻ മെഡിക്കൽ ലിറ്ററേച്ചറിൽ സൂചിപ്പിച്ചിരിക്കുന്ന വിവിധ മരുന്നുകൾ ലഭ്യമാക്കുന്നതിനുള്ള ശ്രമങ്ങളും നടത്തിയിട്ടുണ്ട്. ഗവേഷണ സംഘടനകളുമായി സഹകരിച്ച് സ്ഥിരീകരണത്തിനായി molecular and genetic diagnosis നൽകാനുള്ള ശ്രമങ്ങൾ തുടരുകയാണ്. അമീബിക് മെനിഞ്ചോ എൻസെഫലൈറ്റിസ് സംബന്ധിച്ച് IEC മെറ്റീരിയലുകൾ സോഷ്യൽ, ഓഡിയോവിഷ്വൽ മാധ്യമങ്ങൾ വഴി പ്രചരിപ്പിച്ചിട്ടുണ്ട്. കൂടാതെ G.O(Rt)No.1760/2024/H&FWD dated 20-07-2024 ഉത്തരവ് പ്രകാരം അമീബിക് മെനിഞ്ചോ എൻസെഫലൈറ്റിസ് തടയൽ, രോഗ നിർണ്ണയം, ചികിത്സ എന്നിവ സംബന്ധിച്ച സാങ്കേതിക മാർഗ്ഗനിർദ്ദേശങ്ങൾ പുറപ്പെടുവിച്ചിട്ടുണ്ട്.


അമീബിക് മസ്തിഷ്കജ്വരത്തിന്റെ ചികിത്സയിൽ വളരെ പ്രധാന പങ്ക് വഹിക്കുന്ന Miltefosin(മൽറ്റിഫോസിൻ) എന്ന മരുന്നിന്റെ ലഭ്യത ആരോഗ്യ വകുപ്പ് ഉറപ്പു വരുത്തിയിട്ടുണ്ട്. ഏകാരോഗ്യ (One health) സമീപനത്തിലൂന്നിയ ഗവേഷണ പ്രവർത്തനങ്ങളും പ്രതിരോധ പ്രവർത്തനങ്ങളും ഏകോപിപ്പിക്കാനായി ICMR, ഇന്ത്യൻ ഇൻസ്റ്റിറ്റ്യൂട്ട് ഓഫ് സയൻസ്, AV Insitute of Pondicherry എന്നിവിടങ്ങളിലെ വിദഗ്ദരെ പങ്കെടുപ്പിച്ച് സാങ്കേതിക ശില്പശാല ആഗസ്റ്റ് 27, 2024 ന് നടത്തി. അമീബയുടെ വളർച്ചയെ സഹായിക്കുന്ന ജൈവികവും അജൈവികവുമായ ഘടകങ്ങളെപ്പറ്റിയുള്ള വിശദമായ റിപ്പോർട്ട് കേരള സർവ്വകലാശാലയുടെ പാരിസ്ഥിതിക എഞ്ചിനീയറിംഗ് വിഭാഗവും സംസ്ഥാന മലിനീകരണ ബോർഡും ചേർന്ന് തയ്യാറാക്കി. ഏകാരോഗ്യ സമീപനത്തിലൂന്നിയ സമഗ്ര കർമ്മ പദ്ധതി സംസ്ഥാനം രൂപീകരിച്ചു. പ്രതിരോധ പ്രവർത്തനങ്ങളുടെയും ബോധവൽക്കരണത്തിന്റെയും ചികിത്സാ മാർഗ്ഗരേഖയുടെയും ഫലമായി 97 മുതൽ 99% വരെയുള്ള മരണ നിരക്ക് 26% ആയി കുറക്കാൻ കേരളത്തിന് കഴിഞ്ഞു.

അമീബിക് മസ്തിഷ്കജ്വരം ബാധിച്ചവർക്ക് സംസ്ഥാനത്തെ മെഡിക്കൽ കോളേജുകളിൽ ചികിത്സാ സൗകര്യം ലഭ്യമാക്കിയിട്ടുണ്ട്. വിശദാംശങ്ങൾ **അനുബന്ധം 3** ആയി ചേർക്കുന്നു.

സർക്കാർ പുറപ്പെടുവിച്ചിട്ടുള്ള സാങ്കേതിക മാർഗ്ഗനിർദ്ദേശങ്ങൾ അനുസരിച്ച് ഏതൊരു Tertiary കെയർ ആശുപത്രിയും അമീബിക് മസ്തിഷ്കജ്വരം ചികിത്സിക്കാൻ കഴിയും.

സെക്ഷൻ ഓഫീസർ

ജില്ല	ചികിത്സ തേടിയവരുടെ എണ്ണം	മരണപ്പെട്ടവരുടെ എണ്ണം
തിരുവനന്തപുരം	17	-
കോഴിക്കോട്	3	1
തൃശൂർ	1	-
കണ്ണൂർ	3	2
മലപ്പുറം	2	2
പാലക്കാട്	1	1

  
 മെഡിക്കൽ ഓഫീസർ



**GOVERNMENT OF KERALA**

**Abstract**

Health & Family Welfare Department - Technical Guidelines on Prevention, Diagnosis and Treatment of Amoebic Meningoencephalitis in Kerala - Orders issued.

---

**HEALTH & FAMILY WELFARE (F) DEPARTMENT**

G.O.(Rt)No.1760/2024/H&FWD Dated,Thiruvananthapuram, 20-07-2024

---

Read Proposal from the Chairperson, State Medical Board

**ORDER**

In the context of reporting Amoebic Meningoencephalitis cases in the State, for ensuring effective control and management of the disease, Government are pleased to issue the "*Technical Guidelines on Prevention, Diagnosis and Treatment of Amoebic Meningoencephalitis in Kerala*" as annexed to this order.

(By order of the Governor)

SHIJA C G

JOINT SECRETARY

To:

The State Mission Director - National Health Mission,  
Thiruvananthapuram.

The Director of Health Services, Thiruvananthapuram.

The Director of Medical Education, Thiruvananthapuram.

The Chairperson, State Medical Board

All District Medical Officers (Health)

Principal Accountant General (A&E/Audit) Kerala.

Information & Public Relations (Web & New Media) Department

Stock File/ Office Copy to file no.F2/219/2024-HEALTH

Forwarded /By order

Signed by

Vilasini K V

Date: 20-07-2024 18:16:03

Section Officer

## TECHNICAL GUIDELINES ON PREVENTION, DIAGNOSIS AND TREATMENT OF AMOEBIC MENINGOENCEPHALITIS IN KERALA

Amoebic encephalitis is a rare but lethal central nervous system infection caused by free-living amoebae found in freshwater, lakes, and rivers. There are two types of amoebic encephalitis, namely primary amoebic meningoencephalitis (PAM) and granulomatous amoebic encephalitis (GAE). Primary amoebic meningoencephalitis (PAM) is a disease caused usually by infection with *Naegleria fowleri*, a microscopic amoeba commonly called a "brain-eating amoeba." This infection destroys brain tissue, causing severe brain swelling and death in most cases. PAM is rare and usually occurs in otherwise healthy children, teens and young adults. The initial symptoms of PAM are indistinguishable from bacterial meningitis, while the symptoms of GAE can mimic a brain abscess, encephalitis, or meningitis. These infections are almost uniformly fatal with only few reported survivors globally.

### Kerala Scenario

Sporadic cases of PAM have been reported from many parts of Kerala in the last decade. As of July 7, 2024, over the last 2 months, five cases of PAM have been reported from North Kerala. Clinical features were suggestive of PAM. The cases over the last 2 months have been reported in children aged 5, 13, 12, 13 and 15 years respectively with a male-to-female ratio of 3:2 [n=5].

### Introduction

---

Free-living amoebae are protozoan environmental parasites, found mainly in freshwater, ponds, lakes, and rivers. There are four main genera of amoebae implicated in human disease, namely *Naegleria* (only *Naegleria fowleri*), *Acanthamoeba* (several species), *Sappinia* (only *S.pedata*), and *Balamuthia* (only *Balamuthia mandrillaris*). Rarely other free-living amoebae (FLA) such as *Vermamoeba [hartmanella] vermiformis* have also been implicated in human disease. The amoebae exhibit CNS tropism leading to meningoencephalitis. *Acanthamoeba* can also cause keratitis and disseminated infections in immunocompromised.

Two distinct clinical syndromes are reported with free-living amoeba infections.

- Primary amoebic meningoencephalitis (PAM)
- Granulomatous amoebic encephalitis (GAE).

*Naegleria fowleri* is the causal agent of primary amoebic meningoencephalitis (PAM), which is an acute, fulminant, and rapidly fatal infection of the central nervous system (CNS). PAM develops following several days of exposure to the contaminated water source and typically causes death within 1-2 weeks of infection. Very few individuals survive the infection, because of its rapid onset and delayed diagnosis. Only 11 survivors of confirmed *N fowleri* PAM have been reported in the literature.

*Naegleria* species are ubiquitous in soil and fresh or brackish water (lakes, rivers, ponds). In general, they are sensitive to environmental conditions such as aridity and pH extremes and cannot survive in seawater. In humans, they are found in the throat and nasal cavity. *N fowleri* is heat-tolerant and can survive temperatures up to 45.8°C, pre-adapting the species to mammalian body temperature. Hence, an incubation temperature of 45°C is routinely used to isolate *N fowleri* from water samples, while suppressing the growth of other amoebae in the samples. As it grows best at elevated temperatures, *N fowleri* has been isolated from warm-water bodies, including man-made lakes and ponds, hot springs, and thermally polluted streams and rivers. It feeds on bacteria in the water bodies for survival. *N fowleri* is not found in saltwater sources such as seawater. Most *N fowleri* infections occur in the summer months.

### **Impact of Global Warming**


The free-living amoeba with the most evidence of the effects of climate change is *N. fowleri*. *N. fowleri* is thermophilic and one of its food sources is cyanobacteria, which flourishes in warmer waters. Climate change raising the water temperature and the heat driving more people to recreational water use is likely to increase the encounters with this pathogen. Furthermore, warming temperatures may be expanding the geographical range of *Naegleria* species. Many reported cases of PAM occurred in the weeks after an increase in air temperature, indicating a potential relation to climate change.

### **Lifecycle of *N.fowleri***

The life cycle of *N. fowleri* consists of 3 stages: trophozoite, a temporary flagellar stage known as amebo-flagellate, and cyst. The active replicating form is a trophozoite that can reproduce asexually. Trophozoite is the vegetative or feeding stage of the amoeba and is the infective form. In humans, this form is found in CSF or in tissue. Cysts are usually absent in clinical specimens, as the infection is so rapid and fatal that the patient typically dies before the trophozoites encyst. The trophozoite can transform into a flagellate stage, in which state it can survive without nutrition. This is also the stage in which the amoeba is distributed through water bodies. In harsher climates, the flagellated form can undergo encystation into a double-walled cyst and withstand



unfavourable conditions. This enables the *N. fowleri* to survive cold temperatures, and nutritively hostile conditions. (Figure 1)



**Figure-1:** Shows the life cycle and infection acquisition of *Naegleria fowleri* (A). The organism lives in the form of a cyst, flagellate or trophozoite state. Freshwater lakes and ponds (B) in summers at high temperatures ~40°C favours the trophozoite forms of *N. fowleri* that can enter the nose during swimming (C), ablution (D) or the water sports of different types (E).

## Pathophysiology

PAM can occur in previously healthy young individuals exposed to warm, especially stagnant, fresh water. The portal of entry by the amoebae is through the olfactory mucosa and the cribriform plate. The oral consumption of water contaminated with *N. fowleri* is not associated with symptomatic disease.

The pathophysiology is thought to be due to an amplified host immune response causing an exaggerated inflammatory reaction, necrotizing encephalitis and subsequent parenchymal damage. It is thought that *N. fowleri* causes an acute inflammatory cytokine response, whereas *Acanthamoeba* and *Balamuthia* spp. cause a type IV hypersensitivity reaction. These inflammatory responses contribute to neuronal damage and subsequent irreversible brain damage.

## Etiology

## Primary meningoencephalitis

*N fowleri* is ubiquitous in soil and is also found in warm freshwater, particularly if the water is stagnant. Exposure to this amoeba is so common that studies have shown that Children younger than 2 years frequently carry the organism asymptotically in their nose and throat, especially in warmer months and climates without getting infected. Infection with this pathogen occurs in both immunocompromised and immunocompetent individuals.

PAM is an exceptionally uncommon occurrence resulting from CNS invasion of the host by *N fowleri*. During a period of a few days to 2 weeks after inoculating a patient who had been swimming, diving, bathing, or playing in warm, usually stagnant, freshwater, the amoebae migrate through the cribriform plate, along the fila olfactoria and blood vessels, and into the anterior cerebral fossae, where they cause extensive inflammation, necrosis, and hemorrhage in the brain parenchyma and meninges.

Case reports have detailed rare infections following ritual ablution with tap water instilled into the nostrils. Similarly, sinus irrigation with contaminated tap (or other) water using neti pots (or similar devices) has been implicated as the mode of inoculation resulting in PAM.

## Granulomatous amebic encephalitis

In contrast to PAM, GAE results from one of the following two pathways. With acanthamebic keratoconjunctivitis, amoebae may spread directly from the cornea to the CNS, though this is uncommon. More typically, GAE results from hematogenous seeding of the CNS following primary inoculation of the lungs or skin by *B mandrillaris*, *Acanthamoeba*, or *Sappinia* species. Once in the CNS, the pathogen results in focal granuloma and abscess formation. GAE more commonly occurs in immunocompromised hosts; however, GAE may also affect otherwise healthy hosts.

**Table 1. Probable Water Exposures-Activity and Water Source-for Reported Cases of Primary Amoebic Meningoencephalitis**

Exposure and Category	n (%)
<b>Water activity (N = 247)</b>	
Swimming/diving	143 (58)
Bathing <sup>a</sup>	40 (16)
Water sports (eg, waterskiing, wakeboarding, jet skiing)	24 (10)
Nasal irrigation	22 (9)
Splashing	12 (5)
Water festival	2 (1)
Other	4 (2)
<b>Water source (N = 265)</b>	
Lake/pond/reservoir	119 (45)
Swimming pool <sup>b</sup>	34 (13)
Tap water <sup>c</sup>	32 (12)
Canal/ditch/puddle	32 (12)
River/stream	21 (8)
Geothermal water	20 (8)
Water tank/cistern	5 (2)
Aquatic sports venue	2 (1)

[a. Depending on the setting, the term “bathing” may be used to refer to cleaning oneself or swimming. It was not possible to distinguish these definitions from case reports.

b. Detailed information regarding the operation, management, and condition of the pool at the time of the case-patient exposure was not reported for most cases.

c. Tap water includes water obtained through public water systems (n = 24), wells (n = 6), or boreholes (n = 2).]

In addition to swimming or diving in water bodies contaminated with *N. fowleri*, the use of neti pots for the treatment of sinusitis has been implicated in causing *N. fowleri* infection. The use of nasal plugs and nose clips completely eliminates the risk of infection.

## Epidemiology

Although rare, cases of PAM and GAE have been reported worldwide, reflecting the ubiquity of the organisms. The first case of PAM was described by Fowler and Carter in Australia in 1965 followed by the first case described in the United States in 1966. PAM is more common in warmer regions and in the warmer months of spring and summer. There is no seasonal variation with GAE. The risk for infection has been estimated at 1 case per 2.6 million exposures to *N fowleri*.

### **Sex- and age-related demographics**

The male-to-female ratio of PAM is 2:1 overall. PAM has been reported in infants as young as 4 months and is most commonly observed in the first 3 decades of life, with one study finding the median age of infection was 11 years (range: 4-56 years). The male-to-female ratio of GAE is 5:1 worldwide and can be seen at any age.

### **Clinical presentation and treatment**

The diagnosis of PAM carries a high mortality rate of greater than 97%. The clinical presentation of PAM is often indistinguishable from bacterial meningitis with headache, fever, nausea, and vomiting being the most common presenting signs and symptoms. By the time other more common causes of meningitis are ruled out and the diagnosis of PAM is considered, it is often too late to save the patient from the cerebral edema that quickly develops and causes death. Studies show a median incubation period of 5 days and a median time from onset of symptoms to death of five days. Most patients present to medical care with signs or symptoms indicative of central nervous system involvement. Analysis of cerebrospinal fluid (CSF) usually reveals a high opening pressure, a predominantly neutrophilic pleocytosis, the presence of RBC, elevated protein concentration, and low glucose levels.

**Table 2. Initial Cerebrospinal Fluid Laboratory Findings on Admission for Reported Cases of Primary Amebic Meningoencephalitis (N = 237) by Classification**

Test (Reference Value)	Total (N = 237)		Confirmed (n = 118)			Probable (n = 80)			Suspect (n = 39)		
	n	Median (Range)	n	Median (Range)	P Value	n	Median (Range)	P Value <sup>a</sup>	n	Median (Range)	P Value <sup>b</sup>
Opening pressure (100-200 mm H <sub>2</sub> O)	31	290 (36-570)	11	360 (36-530)	Ref	14	255 (138-570)	.261	6	215 (55-500)	.312
Red blood cell count (0 cells/ $\mu$ L, CSF)	124	212 (0-30 750)	87	212 (0-30 750)	Ref	29	350 (0-24 600)	.392	8	756 (0-2600)	.545
White blood cell count (0-5 cells/ $\mu$ L)	232	1238 (0-30 000)	117	1830 (10-29 000)	Ref	78	1510 (7-30 000)	.296	37	415 (0-22 000)	< .001
% Neutrophils (2% $\pm$ 5%)	181	82 (0-100)	97	80 (12-100)	Ref	64	90 (15-100)	.002	20	73 (0-100)	.104
% Lymphocytes (62% $\pm$ 34%)	128	20 (2-100)	72	20 (2-90)	Ref	38	15 (2-85)	.691	18	65 (5-100)	< .001
Protein (15-60 mg/dL)	215	326 (20-1374)	109	326 (24-1342)	Ref	70	361 (20-1374)	.978	36	115 (20-731)	< .001
Glucose (40-80 mg/dL)	208	29 (0-223)	106	29 (0-180)	Ref	69	22 (0-223)	.401	33	42 (0-185)	.035

Only 27% of U.S. cases were diagnosed before death. These findings indicate that the diagnosis is often considered too late or not at all in patients with meningitis.

**Characteristics of PAM are as follows:**

- PAM commonly affects children and young adults who have previously been healthy[immunocompetent].
- This disease occurs more often during the warmer months of the year and in warmer climates.
- Patients with PAM typically have a history of swimming, diving, bathing, or playing in warm, generally stagnant, freshwater during the previous 1-9 days.
- Rarely, patients with PAM may experience disordered smell or taste.
- Most often, the symptoms of PAM are indistinguishable from those of acute bacterial meningitis.
- The acute onset of PAM occurs over a period of hours to 1-2 days
- The neuro-olfactory route provides *N.fowleri* quick access to the brain and results in impaired adaptive immune response, causing a very rapid disease course.

- *N.fowleri* evokes a pro-inflammatory immune response with extensive brain-tissue damage whereas *Acanthamoeba* evokes a mixed immune response.

### **Granulomatous amebic encephalitis**

The characteristics of GAE include the following:

- It affects individuals of all ages, although those at the extremes of age may be more susceptible
- Persons with debility or immunocompromise may be more susceptible to GAE.
- There is no seasonal variation because the causative pathogens are ubiquitous.
- Individuals with GAE may have keratoconjunctivitis or a skin ulcer or lesion preceding neurologic symptoms.
- A subacute or chronic presentation lasting days or weeks.

### **Clinical Stages of PAM**


Patients with PAM are mostly admitted in a pre-coma state, and no staging system currently exists to classify the disease. Almost all the survivors of PAM in the past 60 years were diagnosed and treated at a pre-cerebral stage. This shows that early diagnosis of PAM and timely initiation of an antimicrobial cocktail might be lifesaving. To facilitate early diagnosis and timely initiation of treatment to utilize the therapeutic window of opportunity, clinical staging has been proposed by researchers from Aga Khan University Medical College [Fig 2]

#### **Clinical Stage I: Nasal Stage (Pre-Cerebral Stage)**

*N. fowleri* gains entry into the human host via the nose and follows the nasal passage. The introduction of water deep into the nasal orifice causes the protist to encounter the nasal mucosa, leading possibly to infection.

## Clinical Stage II: Olfactory stage

In certain cases, *N.fowleri* proceeds from nasal mucosa to olfactory mucosa and bulb. The involvement of the olfactory mucosa and olfactory bulb is a transient stage before the involvement of the brain. This stage is heralded by changes in the olfactory perception (parosmia). Rojas-Hernandez., *et al.* have experimentally used immunohistochemistry in mice infected with *N. fowleri* to characterize the process by which the protist gains entry to the nasal mucosa. It reaches and crosses the cribriform plate, a sieve-like structure that supports the olfactory bulb and contains conduits between the anterior cranial fossa and the nasal passage. The protist reaches the olfactory bulb and begins to replicate. This induces an inflammatory response in patients that together with cytotoxic activity from the amoeba, results in necrosis, focal hemorrhages and exudates formation. Figure 2: Shows the proposed clinical staging of Primary Amoebic Meningoencephalitis (PAM).



**Figure 2:** Shows the proposed clinical staging of Primary Amoebic Meningoencephalitis (PAM). The different stages could help design diagnostic and therapeutic interventions at these stages. Note the nasal, olfactory and cerebral stages occur during the natural course of the disease and can herald signs that could help in rapid diagnosis and prompt treatment to improve the morbidity and mortality associated with PAM.

## Clinical Stage III: Meningoencephalitic stage

*N. fowleri* causes neuronal injury, both through direct cell damage, and by the release of cytotoxic proteins. Cellular debris and these proteins lead to an inflammatory response involving cytokine release, which mediates further

tissue damage. The final stage in the pathogenesis of *N. fowleri* infection is rapidly progressing meningo-encephalitis. The patient presents in this stage after 1 to 2 days from the olfactory stage described above. Herniation and cerebral edema occur due to a severe inflammatory response.

## Diagnosis

Clinicians should have a high index of suspicion for PAM in the setting of acute meningoencephalitis with negative results for bacteria and common viruses, which should prompt the search for amoebae in the CSF. A history of exposure increases the likelihood of PAM, but it is not always obtained. In the current Kerala context, any person with an epidemiological link should be immediately suspected of having PAM.

The diagnosis of PAM is generally established via observation of motile trophozoites on examination of a CSF wet mount preparation immediately after obtaining the sample. A phase-contrast microscope is useful to optimize visualization of the amoeba. Trophozoites tend to lose motility and may resemble leukocytes. Giemsa or trichrome stains help in identifying morphologic features of the trophozoites: 10 to 25 microns in size with a single nucleus and a centrally located nucleolus with no peripheral chromatin.

A polymerase chain reaction (PCR) from the CSF facilitates rapid detection; it can identify the deoxyribonucleic acid (DNA) of *N. fowleri* and other free-living amoeba. *N. fowleri* can also be isolated in non-nutrient agar supplemented with enteric bacteria such as *E.coli* or *Klebsiella*. Serology is not useful for diagnosis.

**The Centers for Disease Control and Prevention recommends microscopic examination of fresh, unfrozen, non refrigerated cerebrospinal fluid (CSF) for presumptive diagnosis. If amoebae are identified, the diagnosis should be confirmed through PCR.**

Imaging findings on computed tomography (CT) and magnetic resonance imaging (MRI) are nonspecific. Brain edema, basilar meningeal enhancement, hydrocephalus, and areas of cerebral infarction have been described. Lesions in the brain tend to be located in the orbitofrontal and temporal lobes, base of the brain, cerebellum, and upper spinal cord. A purulent exudative inflammation



along the leptomeninges and extensive necrosis and hemorrhage of the parenchyma are characteristic pathological findings. Brain tissue can be examined for trophozoites, and brain sections can be stained with immunofluorescent anti-*N. Fowleri* antibodies

### **Differential diagnosis —**

PAM must be distinguished from acute bacterial meningitis. The clinical manifestations and CSF findings of these two entities are similar. Epidemiological exposure may be useful in differentiating the two conditions. Usually, patients with PAM receive treatment for bacterial meningitis before the definitive diagnosis is established.

### **Treatment—**

The optimal approach to treatment of PAM due to *N. fowleri* is uncertain; no studies evaluating the efficacy of single-drug or combination-drug regimens have been performed. The rarity of the disease, delay in diagnosis, fulminant clinical course, and the difficulties in making a rapid diagnosis have hampered the evaluation of drug regimens. In theory, the best drug regimen should include an amebicidal drug (or a combination of drugs) with good in vitro activity that is capable of crossing the blood-brain barrier.

Based on articles published following well-documented survivors as well as extrapolation from experience with treatment of infection due to *Acanthamoeba* and *Balamuthia* infection, the following combination of drugs (in addition to steroids to control cerebral edema) is expected to have maximum clinical efficacy.

- Conventional amphotericin B (1.5 mg/kg/day intravenously [IV] +/- intrathecally)
- Rifampin (rifampicin; 10 mg/kg/day orally in three divided doses or every 24 hours)
- Fluconazole (10 mg/kg/day IV or orally)

- Miltefosine (<45 kg: 50 mg orally twice daily; ≥45 kg: 50 mg orally three times daily)

- Azithromycin (500 mg IV or orally)

The optimal duration of therapy is uncertain; reports range from 9 to 30 days.

Amphotericin B deoxycholate demonstrates the most favorable in vitro activity (with minimum inhibitory concentrations [MICs] in the range of 0.018 to 1 mcg/mL) and is considered the drug of choice. Administration of amphotericin B is warranted as soon as the diagnosis is considered. Liposomal amphotericin B is less effective in animal models and has higher MICs than the conventional preparation. *Acanthamoeba* is not susceptible to Amphotericin B in in vitro studies.

Other active drugs in vitro include the azoles (fluconazole, voriconazole, ketoconazole, posaconazole, and itraconazole), rifampicin, miltefosine, and azithromycin. The in vitro activity of rifampicin is uncertain. Variations in virulence factors and sensitivity to antimicrobials have been postulated to explain clinical outcomes.

Approximately 11 survivors of PAM are reported in the literature. In most of these cases, an early diagnosis was made, and treatment with amphotericin B was initiated promptly; the most frequently used regimen was amphotericin B plus rifampicin (10 mg/kg/day). The synergy of amphotericin B with azoles (fluconazole 10 mg/kg/day) and rifampin has also been described. In one case, intrathecal administration of amphotericin B and miconazole was used. Another report documents five survivors in the United States. It is difficult to recommend a particular regimen but neuroprotective measures, reducing intracranial pressure, and hypothermia have been tried.

The use of miltefosine for the treatment of PAM has been extrapolated from favorable clinical experience with its use in the treatment of *Balamuthia mandrillaris* and *Acanthamoeba* spp infections.

Azithromycin has both animal and in vitro efficacy against *N. fowleri* and appears to be synergistic when administered with amphotericin B. Posaconazole has been found to inhibit the growth of *N. fowleri* in vitro within 12 hours, and experimental murine infection has been cured with posaconazole, suggesting that in the future this drug may replace fluconazole as the azole of choice; further study is needed to confirm these findings.

**Table 3: Treatment of Confirmed Survivors of Primary Amebic Meningoencephalitis (n = 7)**

Ref.	Country of Exposure	Year	Age (y)	Sex	Amphotericin B Route, Duration, days	Azole Route, Duration, days <sup>a</sup>	Azithromycin Route, Duration, days	Miltefosine Route, Duration, days	Rifampin Route, Duration, days	Dexamethasone Route, Duration, days	Symptom Onset to Start of Treatment, days
[19]	Australia	1971	14	M	IV (Unk.) <sup>b</sup> IT (Unk.) <sup>b</sup>	...	...	...	...	...	Unk.
[20]	United States	1978	9	F	IV (9) IT (10)	IV (9) IT (9)	...	...	PO (9)	IV (Unk.) <sup>b</sup>	3
[21]	Mexico	2003	10	M	IV (14)	IV/PO (30) <sup>c</sup>	...	...	PO (30)	IV (Unk.) <sup>b</sup>	0
[22]	United States	2013	12	F	IV (26) IT (10)	IV (26)	IV (26)	PO (26)	IV (26)	IV (4)	2
[23]	United States	2013	8	M	IV (19) IT (5)	IV (19)	PO (19)	PO (19)	PO (19)	IV (29)	5
[24]	Pakistan	2015	25	M	IV (Unk.) <sup>b</sup> IT (Unk.) <sup>b</sup>	Unk. <sup>d</sup> (Unk.) <sup>b</sup>	Unk. <sup>d</sup> (Unk.) <sup>b</sup>	PO (Unk.) <sup>b</sup>	IV (Unk.) <sup>b</sup>	...	3
N/A <sup>e</sup>	United States	2016	16	M	IV (14) IT (10)	IV (28)	IV (28)	PO (28)	IV/PO (28) <sup>c</sup>	IV (4)	2

Abbreviations: IT, intrathecal; IV, intravenous; N/A, not applicable; PO, oral; Unk., unknown.

<sup>a</sup>This included miconazole (n = 1 patient) and fluconazole (n = 5 patients).

<sup>b</sup>Duration of treatment unknown.

<sup>c</sup>Combination of intravenous and oral administration; specific duration of each route unknown.

<sup>d</sup>Route of administration unknown.

**Table 4: Recommended Multidrug Regimen in Patients with PAM**

Recommended treatment for PAM caused by *Naegleria fowleri* infection

A combination of medications is recommended for treatment of *Naegleria fowleri* infections. These drugs have been used in PAM survivors. Many have been found to have antiamebic activity against *Naegleria fowleri* in the laboratory.

Drug	Dose	Route	Maximum Dose	Duration	Comments
Amphotericin B*	1.5 mg/kg/day in 2 divided doses, THEN	IV	1.5 mg/kg/day	3 days	
	1 mg/kg/day once daily	IV		11 days	14-day course
Amphotericin B	1.5 mg once daily, THEN	Intrathecal	1.5 mg/day	2 days	
	1 mg/day every other day	Intrathecal		8 days	10-day course
Azithromycin	10 mg/kg/day once daily	IV/PO	500 mg/day	28 days	

Fluconazole	10 mg/kg/day once daily	IV/PO	600 mg/day	28 days	
Rifampin	10 mg/kg/day once daily	IV/PO	600 mg/day	28 days	
Miltefosine**	Weight < 45 kg 50 mg BID Weight > 45 kg 50 mg TID	PO	2.5 mg/kg/day	28 days	50 mg tablets
Dexamethasone	0.6 mg/kg/day in 4 divided doses	IV	0.6 mg/kg/day	4 days	

\*Conventional amphotericin (AMB) is preferred. When AMB was compared with liposomal AMB against *Naegleria fowleri*, the minimum inhibitory concentration (MIC) for AMB was 0.1 µg/mL, while that of liposomal AMB was 10x higher at 1 µg/mL. Liposomal AMB was found to be less effective in the mouse model and in in vitro testing than the more toxic form of AMB. AMB methyl ester was also found to be less effective in the mouse model. Because the prognosis of *Naegleria fowleri* infection is extremely poor, consider aggressive treatment.

Miltefosine is mildly nephrotoxic and the dosing may need to be adjusted for patients with impaired kidney function. However, few data are available

about the effective dose for amebic infection. The risk of nephrotoxicity should be balanced with the risk for death from PAM.

**Acanthamoeba meningoencephalitis** - a combination of Sulfadiazine + Pyrimethamine + Fluconazole + surgical resection of CNS lesion ± rifampicin. Intravenous/oral cotrimoxazole and flucytosine also may be tried.

### ***Balamuthia mandrillaris***

- Two cases: Flucytosine + Pentamidine + Fluconazole + Sulfadiazine + Azithromycin or Clarithromycin + surgical resection of CNS lesion
- One case: Pentamidine + Fluconazole + Sulfadiazine + Clarithromycin

### ***Sappinia diploidea* (1 case)**

- Azithromycin + Pentamidine + Itraconazole + flucytosine + surgical resection of CNS lesion

### **Supportive treatment**

Along with antimicrobial combination therapy, supportive therapy aimed at reducing intracranial pressure is equally important. In the survivors, along with antimicrobials, aggressive treatment for cerebral edema and the resulting elevated intracranial pressure with dexamethasone, CSF drainage via an external ventricular drain, hyperosmolar therapy with mannitol and 3% saline, moderate hyperventilation (goal PaCO<sub>2</sub> 30-35 mm Hg), and induced hypothermia (32–34°C) etc were administered. Consider the use of induced pentobarbital coma. The intracranial pressure goal is <20 mm Hg. Place nasogastric tube for miltefosine administration.

**Raised ICP** (suspect in altered sensorium, anisocoria, lateral rectus palsy, decorticate or decerebrate posturing, abnormal breathing pattern, hypertension etc.)

- Keep head in mid position and head end elevation 15-30 ° to facilitate venous drainage.
- 3% saline 5ml/kg (especially if BP is low) or mannitol 2.5 to 5 ml per kg
- IF GCS <8 Intubate with Rapid Sequence Intubation raised ICP protocol

- Maintain euthermia/hypothermia [32-34°C], euglycemia, and normal Blood pressure.
- Avoid hypoxia and Hypercarbia.
- Adequate sedo-analgesia.

In case patient deteriorates: GCS < 8, features of raised ICP, Rapid fall in GCS, Intractable seizures	
To consider necrotizing encephalitis with cytokine storm	
May start pulse methylprednisolone 30mg/kg for 3 days*	
Duration and dose of immunomodulators should be decided by institutional medical board	
*Steroids/immunomodulators should be initiated after expert opinion from institutional medical board comprising of Paediatrician/Physician and Neurologist.	

### Prevention of amoebic meningoencephalitis

Measures to prevent primary amoebic meningoencephalitis include the following:

- Avoidance of diving and jumping into stagnant freshwater.
- Consider using nose plugs for unavoidable exposures or pinching your nose shut when diving or swimming in freshwater.
- Keep your head above water when swimming in freshwater, hot springs, and other untreated thermal bodies of water.
- When participating in water-related activities, avoid digging, or stirring up the sediment.
- Use boiled, filtered, or sterile water for nasal or sinus irrigation, not tap water.
- Wading pools should be emptied each day
- Swimming pools/water theme parks and spas should be kept clean, chlorinated and maintained correctly
- keep sprinklers and hoses away from noses.
- Flush still water from hoses before letting children play with them

If you are using unchlorinated water:

- Don't let water go up your nose when showering or washing your face
- Watch children playing with hoses or sprinklers
- Teach children not to squirt water up their nose

### **Recommended SOP**

- A history of nasal exposure to fresh water in the 14 days before symptom onset should be asked of any patient who presents with symptoms of acute meningitis.
- For patients with meningitis who have a history of recent nasal exposure to fresh water, the CSF specimen should undergo rapid testing for *N. fowleri/FLA*. Microbiologist should be immediately alerted about the clinical suspicion before sending CSF sample.
- In patients with clinical and CSF pictures suggestive of bacterial meningitis who are not responding to antibiotics or are rapidly deteriorating, consider PAM even in the absence of exposure to fresh water.
- CSF wet mount examination is to be done on all turbid/opalescent CSF samples.
- All cases diagnosed as PAM through CSF microscopy should be immediately initiated on the recommended multi-drug regimen and supportive therapy aimed at lowering intracranial pressure.
- All cases diagnosed by CSF microscopy should be immediately informed to DSO and the CSF sample should be sent to the reference lab for PCR and genomic sequencing [if needed].
- All cases of PAM should be treated by a multi-disciplinary team [Institutional Medical Board] comprising Physicians/ Paediatricians, intensivists, ID specialists, Neurologists and Microbiologists.
- Decisions on the use of intrathecal amphotericin B, immunomodulators, therapeutic hypothermia, pentobarbital protocol etc should be taken by the Institutional Medical Board.

## Annexure A

### Wet mount of CSF:


A wet-mount of the CSF should be examined immediately after collection under a microscope (preferably equipped with phase-contrast optics) for the presence of motile *Naegleria fowleri* /other FLA trophozoites.

1. Store CSF at room temperature (~25°C) until examination. Do not refrigerate or freeze.
2. Gently agitate the CSF container to dislodge amoebae adhered to the container.
3. Apply a drop onto a microscope slide.
4. Observe cells for amoeboid movement (directional movements by means of blunt/bulbous pseudopodia) .

Wright stain - Apply a sample of the centrifuged CSF pellet (cytospin) to a slide and prepare a Wright stain using standard protocols. Look for the *N. fowleri*/FLA trophozoite, which can be differentiated from leukocytes by the nucleus that has a large, centrally-placed nucleolus.

### References.

1. Clinical Care of *Naegleria fowleri* Infection, CDC USA.
2. Primary Amoebic Meningoencephalitis (PAM) Clinical Practice Guideline Johns Hopkins All Children's Hospital
3. Cope JR, Ali IK. Primary Amebic Encephalitis: What have we learned in the last 5 years? *Curr Infect Dis Rep* 2016;18:31.
4. Capewell LG, et al. Diagnosis, clinical course, and treatment of primary amoebic encephalitis in the United States, 1937-2013. *J Ped Infec Dis Soc* 2014;1-8.
5. Abdul Mannan Baig and Armaghan-e-Rehman. "Can Clinical Staging of Primary Amoebic Meningoencephalitis be of any Therapeutic Benefit?". *EC Microbiology* 5.3 (2017): 101-108.
6. Epidemiology and Clinical Characteristics of Primary Amebic Meningoencephalitis Caused by *Naegleria fowleri*: A Global Review Radhika Gharpure, John Bliton, Alexandra Goodman, Ibne Karim M. Ali, Jonathan Yoder, and Jennifer R. Cope: *Clinical Infectious Diseases* · May 2020




Handwritten signature and text, possibly a name and date, located at the bottom right of the page.



അമിബിക് മന്ത്രിഷക രോഗത്തിന് ചികിത്സാ സൗകര്യമുള്ള മെഡിക്കൽ കോളേജുകൾ.

1. ഗവ. മെഡിക്കൽ കോളേജ് തിരുവനന്തപുരം.
2. ഗവ. മെഡിക്കൽ കോളേജ്, ആലപ്പുഴ.
3. ഗവ. മെഡിക്കൽ കോളേജ്, കോട്ടയം.
4. ഗവ. മെഡിക്കൽ കോളേജ്, തൃശ്ശൂർ.
5. ഗവ. മെഡിക്കൽ കോളേജ്, കോഴിക്കോട്.
6. ഗവ. മെഡിക്കൽ കോളേജ്, കണ്ണൂർ.
7. ഗവ. മെഡിക്കൽ കോളേജ്, എറണാകുളം.
8. ഗവ. മെഡിക്കൽ കോളേജ്, മലപ്പുറം.
9. ഗവ. മെഡിക്കൽ കോളേജ്, കൊല്ലം.
10. ഗവ. മെഡിക്കൽ കോളേജ്, വയനാട്.

  
മെഡിക്കൽ അമിബിക്